## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.5% below STRENGTH zone (3.0-6.0%); PEG 35.01 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. BAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!**
- Source: KETK.com | 20251207T120829 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Baxter International, Inc. (NYSE:BAX) and some of its officers. The lawsuit, filed on behalf of investors who purchased Baxter securities between February 23, 2022, and October 29, 2025, alleges that the company misled investors regarding defects in its Novum LVP products. Investors who suffered losses have until December 15, 2025, to request to be appointed lead plaintiff.

**2. Securities Fraud Class Action Filed Against Baxter International, Inc. (BAX) - Levi & Korsinsky Reminds Investors of December 15, 2025**
- Source: FOX 2 | 20251207T160814 | Neutral | Relevance: 99%
-  Levi & Korsinsky LLP has filed a securities class action lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors who suffered losses between February 23, 2022, and July 30, 2025. The lawsuit alleges that Baxter made false statements regarding systemic defects in its Novum LVP product, which caused malfunctions and patient harm. Investors are encouraged to learn about their rights before the December 15, 2025, deadline.

**3. Securities Class Action Lawsuit Filed Against Baxter International, Inc. (BAX) â€“ Levi & Korsinsky Represents Shareholders**
- Source: FOX4KC.com | 20251207T000915 | Neutral | Relevance: 99%
- A class action securities lawsuit has been filed against Baxter International, Inc. (NYSE:BAX) by Levi & Korsinsky, LLP, seeking to recover losses for shareholders who purchased stock between February 23, 2022, and July 30, 2025. The lawsuit alleges that Baxter made false statements and concealed systemic defects in its Novum LVP product, which caused malfunctions and patient harm. Shareholders are encouraged to learn about their rights to potentially recover losses.

**4. SueWallSt Podcast Explains Class Action Against Baxter International, Inc. (BAX)**
- Source: WRIC ABC 8News | 20251208T130755 | Neutral | Relevance: 99%
- Levi & Korsinsky, LLP has released a podcast detailing a class action securities lawsuit against Baxter International, Inc. (NYSE:BAX). The lawsuit alleges that Baxter made false statements regarding its Novum LVP product, which suffered systemic defects leading to patient harm. Investors who lost money due to alleged securities fraud between February 23, 2022, and July 30, 2025, are encouraged to contact Levi & Korsinsky.

**5. BAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!**
- Source: FOX 2 | 20251207T120838 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Baxter International, Inc. (NYSE: BAX) for alleged violations of federal securities laws. The lawsuit claims Baxter misled investors about systemic defects in their Novum LVP medical devices, which caused widespread malfunctions and patient harm. Shareholders who purchased Baxter securities between February 23, 2022, and October 29, 2025, have until December 15, 2025, to request to be appointed as lead plaintiff.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.0x requires aggressive growth execution.
2. Elevated short interest (8.6%): bears positioning against stock.
3. Long-term trend broken: trading 32.5% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 35.01 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 8.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.01 |
| Forward P/E | 7.9 |
| Current P/E | 7.7 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.0% to -3.5% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.5pp (needs >3.0% for momentum thesis). Below SMA200 (0.68x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.53% (CS: 18) | Weak |
| RSI_14 | 39.6 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 0.889x | Below |
| vs SMA200 | 0.675x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.16
- **Stop Loss:** $17.00 (6.4% risk)
- **Target:** $19.32 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 431
- **Position Value:** $7,826.96
- **Portfolio %:** 7.83%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*